- Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status
-
Gupta M, Choudhury , Rawal S, Karthikeyan G, Talwar V, Dutta KD, Singh A
- KMID: 2469586
- Nucl Med Mol Imaging.
- 2019 Dec;53(6):423-431.
- doi: 10.1007/s13139-019-00624-8
PURPOSE: The aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance... -
- CITED
-
- Close
- SHARE
-
- Close
